Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 16/20 | 0.50 |
| ▸ | PPARA | Q07869 | 16/20 | 0.50 |
| ▸ | PPARD | Q03181 | 4/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5760525 | 0.93 | PPARG (0.58) | PPARGPPARAPPARDCYP2C9KCNH2 | |
| SCHEMBL5022175 | 0.92 | PPARA (0.49) | PPARGPPARAPPARD | |
| SCHEMBL5015814 | 0.92 | PPARG (0.49) | PPARGPPARAPPARDCYP2C9KCNH2 | |
| SCHEMBL5762723 | 0.91 | PPARG (0.56) | PPARGPPARACYP2C9KCNH2TP53 | |
| SCHEMBL5761021 | 0.91 | PPARG (0.56) | PPARGPPARAPPARDKDR | |
| SCHEMBL5022518 | 0.88 | PPARG (0.48) | PPARGPPARAPPARDCYP2C9KCNH2 | |
| SCHEMBL5759572 | 0.87 | PPARA (0.51) | PPARGPPARAPPARDTP53 | |
| SCHEMBL5015990 | 0.87 | PPARG (0.48) | PPARGPPARAPPARDCYP2C9KCNH2 | |
| SCHEMBL5015996 | 0.87 | PPARG (0.48) | PPARGPPARAPPARDCYP2C9KCNH2 | |
| SCHEMBL5022213 | 0.87 | PPARA (0.51) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392295-B1 | CARBOXYLIC ACID SUBSTITUTED OXAZOLE DERIVATIVES FOR USE AS PPAR-ALPHA AND -GAMMA ACTIVATORS IN THE TREATMENT OF DIABETES | HOFFMANN LA ROCHE (CH) | 2006-05-31 | — | — | EP | disclosed |
| EP-1392295-A1 | CARBOXYLIC ACID SUBSTITUTED OXAZOLE DERIVATIVES FOR USE AS PPAR-ALPHA AND -GAMMA ACTIVATORS IN THE TREATMENT OF DIABETES | F. Hoffmann-La Roche AG (CH) | 2004-03-03 | — | — | EP | disclosed |
| US-6642389-B2 | For therapy of diabetes | HOFFMANN-LA ROCHE INC. | 2003-11-04 | — | — | US | disclosed |
| US-20030055265-A1 | Oxazole derivatives | HOFFMANN-LA ROCHE INC. | 2003-03-20 | — | — | US | disclosed |
| WO-2002092084-A1 | CARBOXYLIC ACID SUBSTITUTED OXAZOLE DERIVATIVES FOR USE AS PPAR-ALPHA AND -GAMMA ACTIVATORS IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055265-A1 | Oxazole derivatives | PPARD, PPARA, PPARG | PPARG 3/4885PPARA 2/4885PPARD 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.